Key result
Accelerated biological aging is linked to ~17% higher CVD risk compared with normal aging.
Why the study?
Does accelerated clinical biomarker-based biological age and aging trajectory increase the risk of cardiovascular disease and all-cause mortality in Chinese adults?
Cohort (n=75,537)
Does accelerated clinical biomarker-based biological age and aging trajectory increase the risk of cardiovascular disease and all-cause mortality in Chinese adults?
Answers are grounded in this paper and cite their sources.
Accelerated biological aging and persistently high aging trajectories are associated with increased risks of cardiovascular disease and all-cause mortality, while lowering aging state mitigates these risks.
BACKGROUND: Evidence on the association of clinical biomarker-based biological age (BA) with cardiovascular disease (CVD) and mortality remains insufficient, particularly concerning aging trajectories' relationship with these two outcomes. METHODS: Seventy-five thousand five hundred thirty-seven Chinese adults from the Kailuan study who participated in the first checkup (2006-2007) were included. BA was predicted by 32 clinical indicators using deep neural networks models. Aging status was divided into decelerated, accelerated, and normal aging based on BA in the first checkup. Six aging trajectories were developed in the initial three checkups. CVD and mortality were followed up till December 31, 2021. RESULTS: After adjusting for chronological age, sex, education level, occupation, physical activity, smoking status, alcohol consumption, salt consumption habit, history of hypertension, diabetes, and dyslipidemia, as well as the use of antihypertensive, antidiabetic, and lipid-lowering drugs, Cox proportional hazard models showed that relative to normal aging, accelerated aging was a risk factor for CVD (adjusted hazard ratio [aHR], 1.17 [95% CI 1.11-1.23]) and mortality (aHR, 1.17 [1.12-1.22]), while participants with decelerated aging had a lower risk for CVD (aHR, 0.85 [0.80-0.90]) and mortality (aHR, 0.86 [0.82-0.90]). Relative to low-stable trajectory, other aging trajectories associated with higher risk of CVD and death, and high-stable trajectory associated with the highest risk of CVD (aHR, 1.62 [1.45-1.81]) and mortality (aHR, 1.55 [1.41-1.71]). Relative to high-stable trajectory, high-decreasing trajectory was associated with lower risk of CVD (aHR, 0.76 [0.67-0.86]) and death (aHR, 0.78 [0.70-0.87]), and decreasing-increasing trajectory was associated with lower risk of death (aHR, 0.86 [0.75-0.98]). CONCLUSIONS: Accelerated BA aging is associated with a higher risk of CVD and mortality, whereas decelerated aging is associated with a lower risk compared to normal aging. Those persistently at high aging levels are at the highest risk for both CVD and death; conversely, it is the act of lowering and continually maintaining a reduced aging state that effectively mitigates these risks.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2025) conducted a cohort in Cardiovascular disease and all-cause mortality (n=75,537). Accelerated biological aging vs. Normal aging was evaluated on Cardiovascular disease (CVD) (HR 1.17, 95% CI 1.11-1.23). Accelerated biological aging was associated with a higher risk of cardiovascular disease and mortality compared to normal aging.
Synapse has enriched 10 related papers. Consider them for comparative context: